Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Muparfostat

Next Previous
X
Search
Drug Profile

Muparfostat

Alternative Names: Mannopentaose phosphate sulfate; Muparfostat sodium; Phosphomannopentaose sulfate; PI-88; PI-88 sodium; PI88-cpd; Sulfated mannopentaose phosphate

Latest Information Update: 05 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Australian National University
  • Developer Medigen Biotechnology Corporation; Progen Pharmaceuticals; Progen Pharmaceuticals Limited; TBG Diagnostics Limited
  • Class Antineoplastics; Antithrombotics; Mannans; Oligosaccharides
  • Mechanism of Action Fibroblast growth factor inhibitors; Heparanase inhibitors; Heparin cofactor II stimulants; Lipoprotein-associated coagulation inhibitor stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase I/II Solid tumours
  • Discontinued Cardiovascular disorders; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Thrombosis

Most Recent Events

  • 23 Jun 2022 Cellxpert Biotechnology completes a phase II trial in Liver cancer in Taiwan (NCT00247728)
  • 09 Aug 2017 Adverse events and efficacy data from the phase III PATRON trial in Liver cancer released by Medigen Biotechnology
  • 08 Aug 2017 Adverse events data from a phase II trial in Liver cancer released by Medigen Biotechnology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top